Lanwei Medical (Stock Code: 301060) is a leading integrated service provider in the inspection and diagnosis industry, providing third-party medical testing and pathological diagnosis services, as well as in vitro diagnostic products and other professional technical support of well-known brands at home and abroad. After years of development, the company has established a systematic, large-scale and networked service system, which is committed to becoming an effective supplement to public medical institutions and providing comprehensive inspection and diagnosis projects and professional services for medical institutions. Now let's take a look at the financial data reported by Lanwei Medical in 2023.

First of all, we see that the total closing balance of the company's assets is 3.221 billion yuan, which is lower than the 3.747 billion yuan at the beginning of the period. The total balance at the end of the period was 1.089 billion yuan, which was also lower than that of 1.474 billion yuan at the beginning of the period. These two figures show that the company's assets and liabilities decreased during the reporting period.

Secondly, we see that the balance of the company's net assets at the end of the period is 2.132 billion yuan, which is less than the 2.273 billion yuan at the beginning of the period. This may be due to a decrease in net assets as a result of the company's operating activities during the reporting period.

Next, we see that the company's asset-liability ratio at the end of the period was 33.81%, down from 39.34% at the beginning of the period. This shows that the ratio of liabilities to assets decreased and the financial structure of the company improved during the reporting period.

Then we saw that the company's gross margin was 25.71% in the reporting period, down from 46.77% in the same period last year. This may be due to an increase in operating costs or a decrease in operating income during the reporting period.

Looking at the company's net interest rate, the company's net interest rate for the reporting period was-2.12%, down from 25.56% in the same period last year. This shows that the ratio of the company's net profit to operating income has decreased during the reporting period, and the company's profitability has weakened.

Then we saw that the company's return on equity (ROE) was-0.81% at the end of the period, down from 28.58% at the beginning of the period. This shows that the ratio of the company's net profit to net assets decreased during the reporting period, and the company's profitability weakened.

Finally, we see that the goodwill balance of the company at the end of the period is 2520 million yuan, an increase compared with the 176 million yuan at the beginning of the period. This may be due to the increased goodwill of the company through mergers and acquisitions or investment activities during the reporting period.

To sum up, Lanwei Medical's overall financial position during the mid-reporting period in 2023 was stable, but its profitability declined. For investors, they need to pay attention to the changes of the company's profitability and financial situation in the future in order to make reasonable investment decisions.

This article only represents the judgment made by the analyst himself or the analyst on the basis of AI analysis, and can not be used as any investment index, nor does it constitute any investment advice. The original intention of this paper is to help investors analyze and judge the capital market data in the most intuitive and fast way and from the most professional perspective.